Mr. Kamal was previously president of Prime Therapeutics and CEO of subsidiary MagellanRx.
Current CEO Ken Paulus plans to retire, according to a July 3 news release.
“Our newly combined organization has the right solutions, scale and know-how to be a powerful player in this market. I’m excited to lead the exceptionally talented teams that are making that vision a reality,” Mr. Kamal said in the release.
Prime Therapeutics, which is jointly owned by 19 Blue Cross Blue Shield companies, purchased MagellanRx from Centene in 2022.
At the Becker's 5th Annual Fall Payer Issues Roundtable, taking place November 2–3 in Chicago, payer executives and healthcare leaders will come together to discuss value-based care, regulatory changes, cost management strategies and innovations shaping the future of payer-provider collaboration. Apply for complimentary registration now.
